Drug intelligence / Profile preview

Calmeva

Development stage
Unknown
Lead developer
FARMA-DERMA
Modality
Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
Administration
Vaginal
01

Overview

Calmeva (marketed as Cicatridina in other regions) is a hormone-free vaginal ovule formulation developed by Farma-Derma and licensed to Instituto Biológico Argentino (Biol) in Argentina. It is indicated as an adjuvant treatment for the repair and healing of atrophic and dystrophic states of the vaginal mucosa. The formulation combines sodium hyaluronate (hyaluronic acid) with botanical extracts including Centella asiatica, Calendula, Aloe vera, and Melaleuca (tea tree oil). Hyaluronic acid acts as a structural support, providing hydration, tone, and elasticity to accelerate tissue repair and re-epithelialization, while the botanical components offer soothing, anti-inflammatory, and antimicrobial properties to relieve vaginal dryness, itching, and irritation.

Brand names
CalmevaCicatridina
Other names
hyaluronic acid + aloe vera + calendula + centella asiatica + tea tree oilsodium hyaluronate + aloe vera + calendula + centella asiatica + tea tree oil

Beyond the preview

Go deeper on Calmeva.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Calmeva.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call